Riskpilot← Back to searchSign inGet full accessOTSUKA PHARMA SCANDINAVIA AB
ABActiveOrg 5566158134Sveavägen 151Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200139 employees
Revenue 2024
SEK 367,4M
+10% vs 2023
EBITDA margin
2.8%
+15% vs 2023
Equity ratio
36.6%
Financial strength
Net profit 2024
SEK 7,5M
+12% vs 2023
| Revenue | SEK 367,4M | +10% |
| EBITDA | SEK 10,2M | +15% |
| Net profit | SEK 7,5M | +12% |
| Total assets | SEK 136,4M | +3% |
| Equity | SEK 49,9M | +2% |
| Employees | 39 | — |
Legal name
OTSUKA PHARMA SCANDINAVIA AB
Org number
5566158134
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11 september 2001
Share capital
SEK 100 000
Employees
39 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Neumann, Christian Michael Nilsson, Anna Teresia
Company purpose
Bolaget ska bedriva försäljning, marknadsföring, forskning och utveckling av medicinsk utrustning och läkemedel samt all därmed förenlig verksamhet.
Address
Sveavägen 151
Email
finance@otsuka.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 298 763 | 285 068 | 321 713 | 334 858 | 367 404 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 7 052 | 9 885 | 12 142 | 8 874 | 10 231 |
| Depreciation & amort. | −1 036 | −453 | −382 | −301 | −477 |
| EBIT | 6 016 | 9 432 | 11 760 | 8 573 | 9 754 |
| Net financials | −132 | −205 | 13 | 538 | 639 |
| Profit before tax | 5 923 | 9 227 | 11 773 | 9 111 | 10 393 |
| Tax | −1 493 | −2 120 | −2 907 | −2 451 | −2 913 |
| Net profit | 4 430 | 7 107 | 8 866 | 6 660 | 7 480 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 103 252 | 103 287 | 121 328 | 131 928 | 136 409 |
| Equity | 44 462 | 49 354 | 51 220 | 49 015 | 49 895 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 58 790 | 53 933 | 70 108 | 82 913 | 86 514 |
| Total debt | 58 790 | 53 933 | 70 108 | 82 913 | 86 514 |
EBITDA margin
2.8%
This company
15.8%
Market median
-82% vs market
20202024
Equity ratio
36.6%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
15.0%
This company
18.4%
Market median
+18% vs market
20202024
Net profit margin
2.0%
This company
8.1%
Market median
-75% vs market
20202024
Asset turnover
2.69×
This company
1.12×
Market median
+140% vs market
20202024
Debt / equity
1.73×
This company
0.62×
Market median
-179% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HE Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
JE Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Chairman | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
OTSUKA PHARMACEUTICAL EUROPE LTD
OTSUKA PHARMA SCANDINAVIA AB (this company)Board members of OTSUKA PHARMA SCANDINAVIA AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Evert Blom | Chief Auditor | 0 companies |
| John Erik Christian Lundin | Chief Auditor | 0 companies |
| Karl Pontus Billstam | Chairman | 0 companies |
| Anna Teresia Nilsson | Chairman | 0 companies |
| Nicholas Ian Craig | Board of Directors | 0 companies |
| Christian Michael Neumann | Deputy Board Member | 0 companies |